Nuvectis Pharma (NVCT) Change in Account Payables (2023 - 2026)
Nuvectis Pharma (NVCT) posted Change in Account Payables of -$1.6 million for Q1 2026, down 856.97% sequentially from -$165000.0 in Q4 2025, and down 419.64% YoY from $494000.0 in Q1 2025.
Nuvectis Pharma (NVCT) Change in Account Payables (2023 - 2026) Analysis & Trends
Nuvectis Pharma has reported Change in Account Payables for 4 years, with the latest figure at -$1.6 million in Q1 2026.
- Quarterly Change in Account Payables fell 419.64% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 38.12% YoY) and the FY2025 annual result came in at $3.8 million, up 1483.15% from the prior year.
- Change in Account Payables eased to -$1.6 million in Q1 2026 per NVCT's latest filing, from -$165000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $2.0 million in Q2 2025 and troughed at -$1.6 million in Q1 2026.
- A 4-year average of $137307.7 and a median of $87000.0 in 2024 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2025 and 2026: Change in Account Payables surged 2181.61% in 2025, then slumped 419.64% in 2026.
- Over 4 years, Change in Account Payables stood at -$721000.0 in 2023, then jumped by 132.87% to $237000.0 in 2024, then plunged by 169.62% to -$165000.0 in 2025, then slumped by 856.97% to -$1.6 million in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$1.6 million, -$165000.0, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | 489,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 489,000.00 |
| Jun 30, 2026 | 489,000.00 |
| Mar 31, 2026 | -1.58 Mn |
| Mar 31, 2026 | -1.58 Mn |
| Dec 31, 2025 | -165,000.00 |
| Dec 31, 2025 | -165,000.00 |
| Sep 30, 2025 | 1.46 Mn |
| Sep 30, 2025 | 1.46 Mn |
| Jun 30, 2025 | 1.99 Mn |
| Jun 30, 2025 | 1.99 Mn |
| Mar 31, 2025 | 494,000.00 |
| Mar 31, 2025 | 494,000.00 |
| Dec 31, 2024 | 237,000.00 |
| Dec 31, 2024 | 237,000.00 |
| Sep 30, 2024 | 415,000.00 |
| Sep 30, 2024 | 415,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Mar 31, 2024 | -1.01 Mn |
| Mar 31, 2024 | -1.01 Mn |